A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Feb 2018 Status changed from active, no longer recruiting to recruiting.
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 17 May 2016 Status changed from not yet recruiting to recruiting.